FDA Approves Niraparib for Advanced Ovarian Cancer

April 29, 2020 10:00 am

By Hannah Slater

The FDA approved niraparib (Zejula) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.1

Efficacy for … Read more

Blood Test Helped Detect Cancer Before Symptoms, Study Finds

April 28, 2020 10:45 am

by Marilynn Marchione

For the first time, a blood test has been shown to help detect many types of cancer in a study of thousands of people with no history or symptoms of the disease.

The test is still experimental. … Read more

AACR 2020: Cell-Free DNA Liquid Biopsy May Provide an Early Detection Test for Patients With Suspected Cancer

April 28, 2020 10:30 am

By Jo Cavallo

The Circulating Cell-free Genome Atlas Study is a large multicenter, case-controlled, observational study of 15,254 participants, 56% with cancer and 44% without cancer, with longitudinal follow-up to support the development of a cell-free DNA (cfDNA) multicancer early … Read more

Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at the AACR 2020 Virtual Annual Meeting I

April 27, 2020 10:20 am

BOSTON–(BUSINESS WIRE)– Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced results from the ongoing investigator-initiated Phase 1 clinical study investigating VS-6766, its

Read more

STRO-002 Shows Encouraging Results in Phase I Trial in Treatment of Ovarian Cancer

April 27, 2020 10:15 am

By Peter Hofland, Ph.D

Updated interim data from an ongoing Phase I dose-escalation phase clinical study (NCT03748186) evaluating the folate receptor alpha (FRα) antibody-drug conjugate (ADC) STRO-002 (Sutro Biopharma) shows encouraging results.[1]

The trial was designed to study … Read more

MD Anderson, Ipsen Advance New Therapy With Potential Benefit for Underserved Lung and Ovarian Cancer Patients

April 26, 2020 10:30 am

In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development … Read more

Abclon Derives Clinical Materials for CAR-T Treatment of Ovarian Cancer

April 21, 2020 6:00 pm

By Shim Hyun-tai

Antibody-based therapeutics developer Abclon said Tuesday that it has successfully drawn final candidates for the clinical trials of the next-generation chimeric antigen receptor T (CAR-T) cell therapy for ovarian cancer.

Abclon plans to enter clinical trials in … Read more

New Standard in Recurrent, Platinum-Sensitive Ovarian Cancer

April 21, 2020 10:00 am

By Pam Harrison

Replacing gemcitabine (Gemzar) with pegylated liposomal doxorubicin in a standard platinum-based regimen improved survival in recurrent ovarian cancer, a phase III trial has shown.

In a cohort of nearly 700 women receiving carboplatin plus bevacizumab (Avastin), median … Read more

Gemcitabine–Pazopanib Combo Shows Antitumor Efficacy in Ovarian Cancer

April 17, 2020 11:00 am

Toronto, Canada—Findings from a phase 2 study prepared for presentation at the 2020 SGO Annual Meeting on Women’s Cancer showed that adding pazopanib to gemcitabine enhanced antitumor activity in patients with ovarian cancer.

“Angiogenesis inhibition is a valuable strategy for … Read more

Olaparib Matches Chemotherapy Outcomes in Platinum-Sensitive Recurrent Ovarian Cancer

April 17, 2020 10:30 am

By Lisa Astor

Treatment with olaparib demonstrated similar outcomes to standard-of-care chemotherapy treatment in patients with BRCA wild-type, platinum-sensitive, recurrent epithelial ovarian cancer in the phase II CLIO study. As such, olaparib failed to demonstrate a significant improvement in survival Read more

Drug May Help Overcome Chemo Resistance in Ovarian Cancer

April 17, 2020 10:00 am

Scientists from Mater Research – The University of Queensland, have discovered they can overcome chemotherapy resistance in an ovarian cancer subtype by using low doses of a drug which slows cell growth.

Led by Professor John Hooper, the TRI-based Mater … Read more

New Cancer Drug Shrinks Tumors, Reduces Side Effects, in Animal Studies

April 15, 2020 10:00 am

By Brita Belli

A class of experimental cancer drugs called BET inhibitors have shown promise for treating cancers of the blood, but can induce toxic side effects. Now Yale researchers have found a new inhibitor that in animal studies demonstrates … Read more

Frontline Niraparib Plus Bevacizumab for Advanced Ovarian Cancer Yields Promising Activity

April 13, 2020 12:00 pm

By Gina Columbus

Frontline niraparib in addition to bevacizumab as maintenance demonstrated impressive clinical activity in patients with advanced ovarian cancer who achieved either a complete or partial response to frontline platinum-based chemotherapy with bevacizumab, according to the phase II Read more

Olaparib/Bevacizumab as Frontline Maintenance Improves PFS in Ovarian Cancer, Regardless of Timing of Surgery, Disease Status

April 8, 2020 10:00 am

By Gina Columbus

The combination of olaparib (Lynparza) and bevacizumab (Avastin) was found to improve progression-free survival (PFS) outcomes versus bevacizumab alone as a frontline maintenance treatment in patients with newly diagnosed advanced high-grade serous ovarian cancer, regardless of the … Read more

Certain STIs May Play a Role in Ovarian Cancer Development

April 7, 2020 10:00 am

By Leah Lawrence

History of sexually transmitted infections (STIs) may be important in the etiology of ovarian cancer — and a new study links certain STIs with increased risk for the disease.

Using data from the European Prospective Investigation into … Read more

Trametinib Boosts PFS and Response Rates in Low-Grade Ovarian Cancer

April 7, 2020 10:00 am

By Denise Myshko

Trametinib (Mekinist) monotherapy has emerged as a new treatment option for women with recurrent low-grade serous ovarian cancers based on improvements in survival outcomes and response rates demonstrated in a phase II/III study, according to David M. … Read more

Analysis Pinpoints Veliparib Antitumor Activity in Ovarian Cancer

April 6, 2020 10:00 am

By Jason M. Broderick

Adding veliparib to frontline induction chemotherapy increased complete and CA-125 responses compared with chemotherapy alone in patients with high-grade serous ovarian cancer, according to an exploratory analysis of the phase III VELIA trial.1

The 3-arm … Read more

Water-Only Fasting May Reduce Chemo Modifications, Hospital Admissions

April 3, 2020 10:00 am

By Neil Osterweil

FROM SGO 2020

Patients with gynecologic malignancies who consumed only water for 24 hours before and 24 hours after each chemotherapy cycle had fewer dose delays and reductions compared with patients who didn’t fast, results of a

Read more

Advanced Ovarian Cancer: Survival & NAC Use Continue to Increase

April 2, 2020 11:00 am

By Pam Harrison

Uptake of neoadjuvant chemotherapy (NAC) for the treatment of advanced ovarian cancer has increased dramatically since 2006 in the United States, but importantly, the median survival has also continued to increase, new research shows.

These trends confirm … Read more